Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.
Medivation recognizes the importance of collaborations to maximize the global potential of our product candidates.
In October 2009, Medivation announced a global agreement with Astellas Pharma Inc. to develop and commercialize MDV3100, our investigational drug for the treatment of prostate cancer. Under the terms of the agreement, we received an up-front cash payment of $110 million and are eligible to receive payments of up to $335 million upon the attainment of development and regulatory milestones plus up to an additional $320 million in commercial milestone payments. We will collaborate on a comprehensive development program that will include additional studies to develop MDV3100 for both late- and early-stage prostate cancer. Subject to receipt of regulatory approval, we will jointly commercialize MDV3100 in the U.S. We will share equally all U.S. development costs, commercialization costs, and profits. Astellas will have responsibility for developing and commercializing MDV3100 outside the U.S. and will pay us tiered double-digit royalties on ex-U.S. sales.
|
 |
 |
| Medivation © 2012 |